
Investors should exercise extreme caution regarding Hims & Hers Health (HIMS) following a proposal by the CFO to liquidate 75% of his personal shareholdings. This high-volume insider selling serves as a significant red flag, suggesting a potential lack of executive confidence in the company’s future valuation. The company faces high product concentration risk, as revenue remains heavily dependent on hair loss treatments like finasteride and minoxidil. You should monitor whether these sales are part of a scheduled 10b5-1 plan or discretionary, as the latter indicates a more urgent exit. Consider reducing exposure or tightening stop-losses to protect against downward price pressure resulting from this shift in leadership sentiment.

By @notthreadguy
Stocks, crypto, politics, culture, and the great financialization of everything. Threadguy is live every weekday from New York with analysis, commentary, and interviews with leading figures across the space of internet markets.